11.39USD+1.52%Mkt Cap: 1.71B USDP/E: —Last update: 2026-06-01
Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which i…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap1.71B USD
Enterprise Value1.60B USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-738.82M USD
Revenue/Share—
Last Price11.39 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees274
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-5.64
PEG—
EV/EBITDA-2.63
EV/Revenue—
P/S—
P/B12.80
EPS (TTM)-5.57
EPS (Forward)-1.95
52W Range
7.48035% of range18.57
52W High18.57 USD
52W Low7.480 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-1418.85%
ROA-163.66%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-609.44M USD
CapEx (TTM)715.00K USD
FCF Margin—
FCF Yield-22.18%
Net Debt-61.64M USD
Net Debt/EBITDA0.10
Balance Sheet
Debt/Equity5.47
Current Ratio7.41
Quick Ratio6.68
Book Value/Sh0.8600 USD
Cash/Share2.310 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.7 (Buy)
Target (Mean)21.71 USD
Target Range9.000 USD – 50.00 USD
# Analysts17
Ownership
Shares Out.150.56M
Float124.00M
Insiders11.08%
Institutions97.63%
Short Interest
Short Ratio12.8d
Short % Float20.50%
Short % Out.16.00%
Shares Short24.10M
Short (prev mo.)23.78M
Technical
SMA 509.534 (+19.5%)
SMA 20011.83 (-3.7%)
Beta3.31
S&P 52W Chg27.70%
Avg Vol (30d)1.93M
Avg Vol (10d)2.85M
Technical Indicators
RSI (14)62.7
MACD0.2097
MACD Signal-0.0412
MACD Hist.+0.2509
BB Upper11.18 USD
BB Middle9.587 USD
BB Lower7.995 USD
BB Width33.21%
ATR (14)0.7915 USD
Vol Ratio (20d)1.59x